An important distinction however, is whether the relatively small effects of Orlistat on predictors of cardiovascular risk, such as HbA1c, blood pressure and cholesterol, are useful surrogate end points as there is no data on cardiovascular morbidity or mortality. High attrition rates call into question the tolerability, efficacy and cost of Orlistat in clinical practice, as does the lack of long-term safety data.
Given the lack of efficacious non-surgical treatments for overweight and obesity, Orlistat does have a place in current clinical practice. Where modest weight loss will benefit those with obesity comorbidity, the addition of Orlistat to a program of lifestyle change, diet and physical activity, should be considered.
An important distinction however, is whether the relatively small effects of Orlistat on predictors of cardiovascular risk, such as HbA1c, blood pressure and cholesterol, are useful surrogate end points as there is no data on cardiovascular morbidity or mortality. High attrition rates call into question the tolerability, efficacy and cost of Orlistat in clinical practice, as does the lack of long-term safety data.Given the lack of efficacious non-surgical treatments for overweight and obesity, Orlistat does have a place in current clinical practice. Where modest weight loss will benefit those with obesity comorbidity, the addition of Orlistat to a program of lifestyle change, diet and physical activity, should be considered.
การแปล กรุณารอสักครู่..
